Profil
Kirk Rosemark is currently working as the SVP-Regulatory Affairs & Quality Assurance at Xencor, Inc. Previously, he held positions as the VP-Regulatory Affairs & Quality Assurance at NeoPharm, Inc. and Exelixis, Inc. from 2003 to 2014.
From 2015 to 2017, he worked as the VP-Regulatory Affairs & Quality Assurance at CymaBay Therapeutics, Inc. and from 2017 to 2019, he served as the Vice President-Regulatory Affairs at BeiGene USA, Inc. Mr. Rosemark completed his undergraduate degree at Cleveland State University.
Aktive Positionen von Kirk Rosemark
| Unternehmen | Position | Beginn |
|---|---|---|
| XENCOR, INC. | General Counsel | - |
Ehemalige bekannte Positionen von Kirk Rosemark
| Unternehmen | Position | Ende |
|---|---|---|
BeiGene USA, Inc.
 BeiGene USA, Inc. Pharmaceuticals: MajorHealth Technology BeiGene USA, Inc. engages in pharmaceutical development. The company is headquartered in Cambridge, MA. | General Counsel | 01.06.2019 |
| CYMABAY THERAPEUTICS, INC. | General Counsel | 01.04.2017 |
| EXELIXIS, INC. | Corporate Officer/Principal | 01.11.2014 |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | General Counsel | 01.01.2014 |
Ausbildung von Kirk Rosemark
| Cleveland State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| XENCOR, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
BeiGene USA, Inc.
BeiGene USA, Inc. Pharmaceuticals: MajorHealth Technology BeiGene USA, Inc. engages in pharmaceutical development. The company is headquartered in Cambridge, MA. | Health Technology |
